Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells

Future Medicinal Chemistry

Volumn 3, Issue 16, 2011, Pages 1987-1993

  Iannucci, Nancy B ^a,b   Ripoll, Giselle V ^c   Garona, Juan ^c   Cascone, Osvaldo ^a   Ciccia, Graciela N ^b   Gomez, Daniel E ^c   Alonso, Daniel F ^c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Therapeutic Peptides Research   (Argentina)

^c UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

(4 VALINE 5 GLUTAMINE) DESMOPRESSIN; ANTINEOPLASTIC AGENT; ARGIPRESSIN; DESMOPRESSIN; TETRAPEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CHIRALITY; CONTROLLED STUDY; DISULFIDE BOND; HUMAN; HUMAN CELL; HYDROPHOBICITY; ISOMER; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DEAMINO ARGININE VASOPRESSIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS;

EID: 81855183800     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.152     Document Type: Article

References (30)

1. Zompra AZ, Galanis AS, Werbitzky O, Albericio F. Manufacturing peptides as active pharmaceutical ingredients. Future Med. Chem. 1(2), 361-377 (2009).
2. du Vigneaud V, Ressler C, Swan JM et al. The synthesis of an octapeptide amide with hormonal activity of oxytocin. J. Am. Chem. Soc. 75, 4879-4880 (1953).
3. Lane W, Robson M. Evaluation and Management of Enuresis. N. Eng. J. Med. 360, 1429-1436 (2009).
4. Vande Walle J, Stockner M, Raes A, Nørgaard, JP. Desmopressin 30 years in clinical use: A safety review. Curr. Drug Saf. 2, 232-238 (2007).
5. Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog. Brain Res. 170, 473-512 (2008).
6. Alonso DF, Skilton G, Farias EF, Bal de Kier Joffê E, Gomez DE. Antimetastatic effect of desmopressin in a mouse mammary tumor model. Breast Cancer Res. Treat. 57, 271-275 (1999).
7. Giron S, Tejera AM, Ripoll GV, Gomez DE, Alonso DF. Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation. J. Surg. Oncol. 81, 38-44 (2002).
8. Hermo GA, Torres P, Ripoll GV et al. Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: A pilot study. Vet. J. 178, 103-108 (2008).
9. Hermo GA, Turic E, Angelico D et al. Effect of adjuvant perioperative desmopressin in locally-advanced canine mammary carcinoma and its relation to histological grade. J. Am. Anim. Hosp. Assoc. 47, 21-27 (2011).
10. Birnbaumer M. Vasopressin receptors. Trends Endocrinol. Metab. 11, 406-410 (2000).
11. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).J. Thromb. Haemos. 1, 682-689 (2003).
12. North WG. Gene regulation of vasopressin and vasopressin receptors in cancer. Exp. Physiol. 85, 27-40 (2000).
13. Petit T, Davidson KK, Lawrence RA, von Hoff DD, Izbicka E. Neuropeptide receptor status in human tumor cell lines. Anticancer Drugs 12, 133-136 (2001).
14. North WG, Fay MJ, Longo KA, Du J. Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide. Cancer Res. 58, 1866-1871 (1998).
15. North WG, Pai S, Friedmann A, Yu X, Fay M, Memoli V. Vasopressin gene related products are markers of human breast cancer. Breast Cancer Res. Treat. 34, 229-235 (1995).
16. North WG, Fay MJ, Du J. MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R. Peptides 20, 837-842 (1999).
17. Keegan BP, Akerman BL, Pequeux C, North WG. Provasopressin expression by breast cancer cells: Implications for growth and novel treatment strategies. Breast Cancer Res. Treat. 95, 265-277 (2006).
18. Taylor AH, Ang VT, Jenkins JS, Silverlights RC, Coombes RC, Luqmani YA. Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res. 50, 7882-7886 (1990).
19. Hruby VJ, Smith CW. Structure-activity relationships of the neurohypophyseal peptides. In: The Peptides: Analysis, Synthesis, Biology. Smith CW (Ed.).Academic Press, Boston, NY, USA. 8, 77-207 (1987).
20. Wang J, Hodges R, Sykes B. Effect of trifluoroethanol on the solution structure and flexibility of desmopressin: A two-dimensional NMR study. Int. J. Peptide Protein Res. 45, 471-481 (1995).
21. Walse B, Kihlberg J, Drakenberg T. Conformation of desmopressin, an analogue of the peptide hormone vasopressin, in aqueous solution as determined by NMR spectroscopy. Eur. J. Biochem. 252, 428-440 (1998).
22. Albericio F, Annis I, Royo M, Barany G. Preparation and handling of peptides containing methionine and cysteine. In: Fmoc Solid Phase Peptide Synthesis. A Practical Approach. Chan WC and White PD (Eds).Oxford University Press, Oxford, UK. 77-114 (2000).
23. Yamamura Y, Nakamura S, Itoh S et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 287(3), 860-867 (1998).
24. Buku A, Yamin N, Gazis D. 4-proline and 4-hydroxyproline analogs of arginine vasopressin: role of the proline substitution in the two beta-turns of vasopressin. Experientia 43, 1218-1219 (1987).
25. Slusarz MJ, Sikorska E, Slusarz R, Ciarkowski J. Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: Influence on receptor-bound conformations and interactions with vasopressin and oxytocin receptors. J. Med. Chem. 49, 2463-2469 (2006).
26. Czaplewski C., Kázmierkiewicz R., Ciarkowski J. Molecular modeling of the human vasopressin V2 receptor/agonist complex. J. Comp. Aid. Mol. Des.12, 275-287 (1998).
27. Thibonnier M, Coles P, Thibonnier A, Shoham M. Molecular pharmacology and modeling of vasopressin receptors. Prog. Brain Res. 139, 179-196 (2002).
28. Vande Walle J, Stockner M, Raes A, Nørgaard JP. Desmopressin 30 years in clinical use: A safety review. Curr. Drug Saf. 2, 232-238 (2007).
29. Alonso DF, Ripoll GV, Garona J, Iannucci NB, Gomez DE. Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr. Pharm. Biotech. doi:PMID 21470136 (2011) (Epub ahead of print).
30. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002).